January 29, 2021
By Julie Steenhuysen
(Reuters) – Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants, giving health officials another weapon to tackle the pandemic.
In the trial of nearly 44,000 volunteers, the [READ MORE]
Read more here: OANN